GALMED PHARMACEUTICALS Ltd. Ordinary Shares (par value NIS 0.01 per share) AT- THE-MARKET EQUITY OFFERING AMENDED AND RESTATED SALES AGREEMENTSales Agreement • May 15th, 2020 • Galmed Pharmaceuticals Ltd. • Pharmaceutical preparations • New York
Reference is made to the At-the-Market Equity Offering Sales Agreement, dated as of December 22, 2017 (the “Original Agreement”), by and between Galmed Pharmaceuticals Ltd., a corporation formed under the laws of the State of Israel (the “Company”), and Stifel, Nicolaus & Company, Incorporated (the “Stifel”), pursuant to which the Company proposed to issue and sell through the Stifel from time to time during the term of the Original Agreement, on the terms and subject to the conditions set forth in the Original Agreement, ordinary shares, par value NIS 0.01 per share. The Company, Stifel and Cantor Fitzgerald & Co. (together with Stifel, collectively, the “Agents”, and each individually an “Agent”) wish to amend and restate the Original Agreement in its entirety as provided hereby.
